For Mining Stocks, the Future's Bleak - Or, Maybe the Future's Brilliant

Source: Mineweb (10/3/08)

George Rogers of Investec reckoned the sector may have already reached its bottom and that the best time to invest is when there is "blood on the streets" - metaphorically we hope! Equities are looking cheap and now may well be a very good time to invest, but one does need to be confident that those companies in which to invest are those with the financial strength to survive the bloodbath.

Speaking at this week's Global Capital conference in London - a reasonably well attended event which boasted some excellent and extremely interesting speakers - an unsurprisingly common theme was the effect the credit crunch is having on the fortunes of mining companies, both big and small, but particularly on the juniors.

Opening the event, Charles Kernot of Evolution Securities speaking on the ‘Future of the Mining Industry' (on the day that Xstrata announced that it was pulling out of its proposed bid for Lonmin over credit worries - but had still bought a substantial stake in the market), pointed out that the Eastern population growth patterns - notably in India and China, but also in many other countries - and the rapidly growing middle class, with typical middle class aspirations, would continue to support above average consumption growth. This, in turn, will filter down again into the minerals sector, notwithstanding the short term problems it is facing from the Western World's current sharp downturn...

The toxic debt situation which has created the current severe downturn, in which many undercapitalised mining and exploration companies may well not survive will not go away quickly and there is likely further grief to be face in the investment sector, but, Kernot averred, "Growth will return". We will face short term price declines still, but industrial prices will improve. He picked gold as the safest investment choice pointing out that London's influential Financial Times which is not known for its support of the yellow metal, seems to have recently "grudgingly accepted" this position too...

George Rogers of Investec reckoned the sector may have already reached its bottom and that the best time to invest is when there is "blood on the streets" - metaphorically we hope! Equities are looking cheap and now may well be a very good time to invest, but one does need to be confident that those companies in which to invest are those with the financial strength to survive the bloodbath...

Align Technology Shares Grind 12.5% Higher after Firm Posts Record Q4 Revenue of $834.5 Million
Source: Streetwise Reports (02/04/2021)

Align Technology shares set a new 52-week high after the company announced financial results that included record FY/20 total revenues of $2.5 billion.

Small-Cap Psychedelic Wellness Company Makes First Acquisition: Ketamine Infusion Centers
Source: Streetwise Reports (02/04/2021)

DELIC aims to become a leader in psychedelic health and wellness clinics.

GW Pharmaceuticals Shares Gain 46% on $7.2 Billion Acquisition by Jazz Pharmaceuticals
Source: Streetwise Reports (02/03/2021)

Shares of GW Pharmaceuticals reached a new 52-week high after the company reported it agreed to be acquired by Jazz Pharmaceuticals in a combination cash and stock deal for $220.00 per share.

Shares of Cassava Sciences traded 207% higher after the firm provided an interim analysis from an ongoing study demonstrating that simufilam improves cognition and behavior in mild-to-moderate Alzheimer's disease patients.

Viela Bio Shares Rise 52% on $3.05 Billion Buyout by Horizon Therapeutics
Source: Streetwise Reports (02/01/2021)

Shares of Viela Bio traded higher after it was announced that the company entered into a definitive agreement to be acquired by Horizon Therapeutics for $53.00 per share.

Algernon Pharmaceuticals, a clinical stage pharmaceutical development company, announced that it has established a clinical research program for the treatment of stroke focused on AP-188 (DMT), a known psychedelic compound. Algernon plans to be the first company globally to pursue DMT for stroke in humans and is planning to begin a clinical trial as soon as possible in 2021.

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness
Source: Streetwise Reports (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.

Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million
Source: Streetwise Reports (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.

Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial
Source: Streetwise Reports (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.

Junior Mining Sector 'the Best Value in the Space'
Source: Streetwise Reports (01/27/2021)

The StreetSmart Live! Broadcast on Jan. 26, 2021, focused on metals and why now is a good time for investors to be looking at them and the mining space. John Newell, independent analyst and portfolio manager, and John Feneck, mining sector expert and president of Feneck Consulting, addressed the status of the current metals market. CEOs of the three metals-focused companies comprising the Metallic Group of Companies—Group Ten Metals, Metallic Minerals and Granite Creek Copper—discussed their projects.